a boy in a blue shirt is standing on a chair in front of a classroom full of children . Alt: a boy in a blue shirt is standing on a chair in front of a classroom full of children and dancing.

Join me for CSE's "Business of Publication Management" course. Topics include: business models & revenue; AI strategy; Financial portfolio management; Succession planning; and more! cse.memberclicks.net/short-course...

#ScholarlyPublishing #AcademicPublishing #CareerDev #OpenAccess #AI

AI Rollout Is a People Problem: A Pulse on All Things AI, Part 2 - The Scholarly Kitchen This post explores the human decisions needed in implementing AI at organizations.

At the end of the day, AI and its impact on scholarly publishing is a people "problem," not a tech problem: scholarlykitchen.sspnet.org/2026/04/08/a...

Thanks to @ethicsdoctorp.bsky.social and @acochran12733.bsky.social for a wonderful Editorial Board meeting at @ascocancer.bsky.social headquarters !

What Publishing Leaders Say About AI When They're Not on Panels: A Pulse on All Things AI - The Scholarly Kitchen Today's post explores issues facing scholarly publishers around AI — using it, layering it, competing against it, and licensing to it.

We are all in this together! Todd Toler and I interviewed 14 colleagues about various aspects of AI in their publishing programs and organizations. Part 1 focuses on strategy, leadership, and licensing. scholarlykitchen.sspnet.org/2026/03/11/w...

I know everything I need to know about someone based on whether they liked this movie. I don't disrespect them or dislike them. I just know.

Counterpoint:

Don’t upload your medical records to any LLM.

That’s fucking insane.

Yeah, this is a good one. We might be able to trust the machines, but not the people building the machines.

Wow. Only 15. Thank you so much for sharing this.

Just keep doing it. I got intrepid and then laughable. 🤷🏻‍♀️

Congratulations, Lisa. Can’t wait to hear more about your plans.

What a mess.

Challenges and Opportunities for Cancer Clinical Trials Development in Latin America | JCO Global Oncology Despite accounting for over 8% of the global population and bearing a growing cancer burden, Latin America (LATAM) contributes <2% of global oncology trial activity and scientific output. Beyond…

Review highlights gaps and opportunities to expand cancer clinical trials in Latin America, a region with rising cancer burden but <2% of global trial activity.
Read more: buff.ly/tVPqGO3

#GlobalOncology #ClinicalTrials #LatinAmerica

JCO Journals are now on BlueSky! Give us a follow. @jco-asco.bsky.social @pamelakunzmd.bsky.social @ethicsdoctorp.bsky.social @hemoncwarner.bsky.social @kvanloonmd.bsky.social

Oh, I agree that the hammer could have fallen at any point. I do think that new pressures on Google in the search area raise the question a little more acutely.

Google Scholar Is Doomed Academia built entire careers on a free Google service with zero guarantees. What could go wrong?

Might Google Scholar be headed to the Google Graveyard? hannahshelley.neocities.org/blog/2025_08...

Can't be, Paul. Schools are gun-free zones and the NRA/GOP is constantly telling us that this makes them LESS safe.

A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗

I don't agree with their peer review model, but the premise here is correct. There are rules of indexing and citation counting that are keeping journals from transforming into modern publication systems.

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

May the odds be ever in your favor.
4% payline at the NCI.

www.cancer.gov/grants-train...

Exclusive: NIH to dismiss dozens of grant reviewers to align with Trump priorities The move would undo years of work, leaving advisory councils understaffed, and without the full expertise needed for reviews.

In an unprecedented move, the NIH will soon disinvite dozens of scientists who were about to take positions on advisory councils that make final decisions on grant applications for the US agency, Nature has learnt.

go.nature.com/3TEw7GN

Can the next governor replace those people on the board? Seems it’s in Virginia residents best interest to have a world class public institution.

Agree. At least a decade of pushing our kids to STEM only. Result: few can critically read or write, entry level computer science/coding jobs were the 1st to get cut with AI, decrease in kids wanting to be physicians.

Yep. Prestige costs money to create (literally: highly-selective journals are more expensive to run in part because of their selectivity, not to mention their staff). And, if gold OA is to be the model, then author or their funders are agreeing to pay per paper for that prestige.

We have life saving cancer drugs and life threatening shortages. See our new op ed with potential solutions in @jco-asco.bsky.social

@lymphomadoc.bsky.social
@ascocancer.bsky.social

ascopubs.org/doi/10.1200/...

There's also a helpful criticism here that, if we have to constantly and meticulously double check the work of AI then is it a tool that really saves us time and effort? And, given that cost/benefit ratio, what are the actual use cases that make using it worthwhile?

‼️ #ASCO25 simultaneous publication by Jacobs et al: 

BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation. Read the full article: ascopubs.org/doi/10.1200/...

For breaking news and expert analysis during #ASCO25, turn to #ASCODailyNews! During and after the Meeting, ASCO Daily News has coverage of all the practice-changing research being presented. Bookmark us now: dailynews.ascopubs.org/meetings/asc... #oncsky

The @ascocancer.bsky.social Ed Book is the highest-quality, peer-reviewed, FREE #oncology #MedEd ever. Whether or not you’re at #ASCO25, don’t miss this resource, #OncSky #MedSky, #MedStudentSky! Drop a 📌 in the comments to bookmark the link for later.

ascopubs.org/toc/edbk/cur...

#OncoAlert

Don't miss it! #ASCODailyNews has your exclusive advanced coverage of important abstracts being presented at #ASCOAM dailynews.ascopubs.org/meetings/asc...